Key result
A case series described 4 young women with peripartum cardiomyopathy and therapy-refractory cardiogenic shock referred for potential VA ECMO support to highlight key points in therapy.
Why the study?
Development of therapy-refractory cardiogenic shock in peripartum cardiomyopathy has been described in only a limited number of cases, prompting the need to detail differences and key points in managing end-stage patients.
Case Report (n=4)
No
This case series describes the therapeutic management and key considerations for using VA ECMO in young women with end-stage peripartum cardiomyopathy complicated by cardiogenic shock.
May guide VA-ECMO decisions in refractory PPCM shock; hypothesis-generating and should not yet change practice.
Peripartum cardiomyopathy (PPCM) occurs toward the end of pregnancy or in the months after delivery without previously known structural heart disease. Development of therapy-refractory cardiogenic shock is described in the literature with a limited number of overall presented cases in this young patient cohort. To provide differences and key points in the therapy of end-stage PPCM patients, we present a case series of four young women with PPCM referred to our department for potential VA ECMO support.
No takes yet. Share an insight, caveat, or question.
Djordjevic et al. (2019) conducted a case report in Peripartum cardiomyopathy with cardiogenic shock (n=4). VA ECMO support was evaluated. A case series described 4 young women with peripartum cardiomyopathy and therapy-refractory cardiogenic shock referred for potential VA ECMO support to highlight key points in therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: